33. Application of Cancer Toxicoepigenomics in Identifying High-Risk Populations

  1. Saura C. Sahu
  1. Mukesh Verma1 and
  2. Krishna K. Banaudha2

Published Online: 8 AUG 2012

DOI: 10.1002/9781118349045.ch33

Toxicology and Epigenetics

Toxicology and Epigenetics

How to Cite

Verma, M. and Banaudha, K. K. (2012) Application of Cancer Toxicoepigenomics in Identifying High-Risk Populations, in Toxicology and Epigenetics (ed S. C. Sahu), John Wiley & Sons, Ltd, Chichester, UK. doi: 10.1002/9781118349045.ch33

Editor Information

  1. Division of Toxicology, Center for Food Safety and Applied Nutrition, Food and Drug Administration, Laurel, Maryland, USA

Author Information

  1. 1

    Methods and Technologies Branch, Epidemiology and Genetics Research Program, Division of Cancer Control and Population Sciences, National Cancer Institute, Bethesda, MD, USA

  2. 2

    Biochemistry and Molecular Biology Department, The George Washington University, Washington, DC, USA

Publication History

  1. Published Online: 8 AUG 2012
  2. Published Print: 7 SEP 2012

ISBN Information

Print ISBN: 9781119976097

Online ISBN: 9781118349045



  • cancer toxicoepigenomics in identifying high-risk;
  • EWAS, measurement of epigenetic changes at genome-wide;
  • epigenetic marks, measurement at different time points;
  • aberrant DNA methylation marks, a hallmark of cancer;
  • toxicity and cancer epigenetics;
  • DNMTs, methyl group to cytosine, polycomb-group in DNMT1;
  • toxicoepigenomics, and contributing factors;
  • participating cohorts' protocols, CpG/genomic instability


This chapter contains sections titled:

  • Introduction: epigenetic mechanisms and cancer

  • Toxicity and cancer epigenetics

  • Advantages of using a cohort consortia approach to studying toxicoepigenomics in cancer

  • Data integration

  • Challenges and future directions

  • References